

Navigating the Evolving Landscape of Atopic Dermatitis: Challenges and Future Opportunities: the 4 th Davos Declaration

Claudia Traidl-Hoffmann¹, Jamie Afghani¹, Cezmi Akdis², Mubeccel Akdis³, Aydin Handan⁴, Katja Baerenfaller³, Heidrun Behrendt⁵, Thomas Bieber², Paul L. Bigliardi⁶, Mei Bigliardi-Qi⁶, Charlotte Bonefeld⁷, Stefanie Bösch⁸, Marie-Charlotte Brüggemann², Sebastian Diemert⁹, Hans-Werner Duchna², Martina Fähndrich¹⁰, Danielle Fehr², Marc Fellmann¹¹, Remo Frei², Lene Garvey⁷, Raschid Gharbo¹², Mehmet Gökkaya¹, Karin Grando², Carole Guillet⁸, Erman Güler¹³, Jan Gutermuth¹⁴, Nadine Herrmann¹⁵, DirkJan Hijnen¹⁶, Claudia Hülpüsch¹, Alan Irvine¹⁷, Erika Jensen-Jarolim¹⁸, Heidi H Kong¹⁹, Hillel Koren²⁰, Claudia Lang², Roger Lauener²¹, Laura Maintz¹⁵, Pierre-Yves Mantel², Emanuel maverakis²², Matthias Moehrenschrager¹², Svenja Müller¹⁵, Kari Nadeau²³, Avidan U. Neumann¹, Liam O'Mahony²⁴, Fahafahantsoa Rapelanoro Rabenja²⁵, Harald Renz²⁶, Claudio Rhyner², Ernst Rietschel², Johannes Ring²⁷, Caroline Roduit²⁸, Mari Sasaki²⁹, Mirjam Schenk², Jens Schroder³⁰, Dagmar Simon³¹, Hans-Uwe Simon³², Milena Sokolowska², sonja stander³³, Martin Steinhoff³⁴, Doris Straub Piccirillo², Alain Taïeb³⁵, Roberto Takaoka³⁶, Martin Tapparo³⁷, Henrique Teixeira⁴, Jacob Thyssen⁷, Stephan Traidl³⁸, Miriam Uhlmann², Willem van de Veen³, Marianne van Hage³⁹, Christian Virchow⁴⁰, Andreas Wollenberg⁴¹, yasutaka mitamura³, Alexander Zink⁴², and Peter Schmid-Grendelmeier²

¹Universität Augsburg Medizinische Fakultät

²CK-CARE AG

³Universität Zürich Schweizerisches Institut für Allergie- und Asthmaforschung

⁴AbbVie Inc

⁵Technische Universität München

⁶University of Minnesota Rochester

⁷University of Copenhagen

⁸University Hospital of Zürich

⁹Almirall Hermal GmbH

¹⁰LEO Pharmaceutical Products Sarath Ltd

¹¹Pfizer Switzerland AG

¹²Hochgebirgsklinik Davos AG

¹³Pfizer

¹⁴Universitair Ziekenhuis

¹⁵Universitätsklinikum Bonn Klinik und Poliklinik für Dermatologie und Allergologie

¹⁶Diakonessenhuis Utrecht Zeist Doorn Locatie Utrecht

¹⁷Trinity College Dublin

¹⁸Medizinische Universität Wien Zentrum für Pathophysiologie Infektiologie und Immunologie

¹⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institutes of Health

- ²⁰Environmental Health LLC
- ²¹Ostschweizer Kinderspital
- ²²University of California Davis
- ²³Stanford University School of Medicine
- ²⁴University College Cork
- ²⁵Faculty of Médecine
- ²⁶Philipps University
- ²⁷Klinikum rechts der Isar der Technischen Universität München Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein
- ²⁸Bern University Hospital
- ²⁹Universitäts-Kinderspital Zürich
- ³⁰Universitätsklinikum Schleswig Holstein Campus Lubeck Klinik für Dermatologie Allergologie und Venerologie
- ³¹Inselspital Universitätsspital Bern Universitätsklinik für Dermatologie
- ³²Universität Bern Institut für Pharmakologie
- ³³University Hospital Münster
- ³⁴Hamad Medical Corporation
- ³⁵University of Bordeaux
- ³⁶Hospital das Clínicas
- ³⁷Bencard Allergie GmbH
- ³⁸Cluster of Excellence RESIST (EXC 2155) Hannover Medical School
- ³⁹Karolinska Institute and Karolinska University Hospital Stockholm
- ⁴⁰Universitätsmedizin Rostock Abteilung Pneumologie und Interdisziplinäre Internistische Intensivmedizin
- ⁴¹Ludwig-Maximilian-University
- ⁴²Technical University of Munich

March 26, 2024

Abstract

Aim: The 4th Davos Declaration, convened during the Global Allergy Forum (GAF) in Davos, aimed to elevate patient care for patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. **Methods:** This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient-centric care. **Results** The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. **Conclusion:** The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to work together to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world.

Hosted file

Traidl-Hoffmann et al. Navigating the Changing Landscape of Atopic Dermatitis_060223.docx available at <https://authorea.com/users/331167/articles/734269-navigating-the-evolving-landscape-of-atopic-dermatitis-challenges-and-future-opportunities-the-4-th-davos-declaration>





